Manufacturing CAR-T cells outside the body requires weeks of complex laboratory processing, costing hundreds of thousands of dollars per patient while potentially weakening the therapeutic cells. This bottleneck has limited access to one of oncology's most promising treatments, particularly for patients whose disease progresses too rapidly for traditional ex vivo manufacturing timelines.
Researchers have engineered lentiviral vectors that can convert a patient's own T cells into CAR-T cells directly within their body, bypassing external manufacturing entirely. The team modified viral delivery systems using envelope proteins from dolphin morbillivirus, combined with camelid-derived nanobodies for precise targeting. These vectors demonstrated remarkable specificity for CD7-expressing T cells while evading immune detection from measles antibodies present in most vaccinated individuals. In preclinical lymphoma models, the approach generated functional CAR-T cells in vivo and achieved therapeutic efficacy comparable to traditionally manufactured cells.
This represents a potential paradigm shift from the current "vein-to-vein" timeline of 3-4 weeks to what could theoretically become same-day treatment. The dolphin morbillivirus pseudotyping is particularly clever, as it shares structural similarities with measles virus but remains immunologically distinct enough to avoid neutralization. However, several significant hurdles remain before clinical translation. The approach requires precise control over which T cell populations get modified, and any off-target effects could be irreversible since the genetic modifications occur directly in patients. Additionally, the long-term persistence and safety profile of in vivo-generated CAR-T cells remains unknown compared to the extensively studied ex vivo manufacturing process.